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PP-006 Adefovir resistance detection in chronic
hepatitis B patients with primary non-response
to adefovir treatment
S. Yang1 *, R.X. Xue1, Q. Wang1, H.C. Xing2, J. Guo2,
W. Xie2, J. Yan2, J. Cheng1. 1Institute of Infectious
Diseases, Beijing Ditan Hospital, Beijing, China, 2Center of
Liver Diseases, Beijing Ditan Hospital, Beijing, China
Background and Objective: There is no consensus on which
kind of chronic hepatitis B (CHB) patients should undergo
drug resistance assay during adefovir treatment. The aim of
this study is to determine adefovir resistance proﬁle in CHB
patients who are primary non-response (decrease in serum
HBVDNA by <2 log10 IU/ml) to adefovir treatment.
Method: Serum samples were collected from 28 CHB
patients who were primary non-response to adefovir
treatment. HBVDNA level was assayed by Cobas Taqman
real time PCR. Nested PCR were performed and direct
sequencing of PCR products and cloning sequencing were
used to identify adefovir resistance. HBV genotype and
subgenotype were identiﬁed by phylogenetic tree analysis
of sequencing results.
Results: Serum samples from 28 patients were collected
(25 males and 3 females). Mean age was 39.54 years
(22 62 years). Mean treatment time of adefovir was
15.11 months (6 28 months). During adefovir treatment,
22/28 cases were HBeAg positive; 3/28 cases were anti-HBe
positive; 1/28 case underwent HBeAg seroconversion and
2/28 cases are both negative for HBeAg and anti-HBeAg.
Mean initial HBVDNA level was 4.70 log10 IU/ml (2.51 8.28).
6/28 patients were infected with B2 genotype HBV and
22/28 patients were with C2 genotype. Adefovir resistance
mutations were detected in 7 cases (25%): rtA181T mutation
in 5 cases; rtA181V mutation in 1 case and rtA181V plus
rtN236T mutations in 1 case. There was no difference in
initial HBVDNA level (4.61 versus 5.69, P > 0.05) between
patients with and without adefovir resistance. HBeAg status
and HBV genotype were not related to adefovir resistance
(both P > 0.05). HBVDNA level decrease (log10 IU/ml)/month
was different between patients with adefovir resistance and
without (0.0195 versus 0.0298, P< 0.05). Especially, there is
no difference in adefovir resistance rate between patients
who are non-response after 6 12 months treatments (3/12)
and patients after >12 months treatments (4/16).
Conclusion: Patients who are non-response to adefovir
treatment may be caused by adefovir resistance mutations,
mainly rtA181T. Adefovir resistance patients had less
HBVDNA decrease per month. And adefovir resistance
mutation may occur after 6 12 months adefovir treatment
as they do after >12 months treatments. Thus adefovir
resistance assay is indicated in patients who are primary
non-response to adefovir after 6 months treatment;
especially in patients who had less HBVDNA decrease.
PP-007 Detection of adefovir resistance in chronic
hepatitis B patients with viral breakthrough
during adefovir treatment
S. Yang1 *, R.X. Xue1, Q. Wang1, H.C. Xing2, J. Guo2,
W. Xie2, J. Yan2, J. Cheng1. 1Institute of Infectious
Diseases, Beijing Ditan Hospital, Beijing, China, 2Center of
Liver Diseases, Beijing Ditan Hospital, Beijing, China
Background and Objective: To analyze the adefovir
resistance proﬁle in Chinese chronic hepatitis B (CHB)
patients with viral breakthrough during adefovir treatment
and the correlation between HBV genotype and adefovir
resistance.
Method: Serum samples were collected from CHB
patients who underwent viral breakthrough during adefovir
treatment. HBVDNA level was assayed by Cobas Taqman
real time PCR. Nested PCR were performed and direct
sequencing of PCR products and cloning sequencing were
used to identify adefovir resistance. HBV genotype and
subgenotype were identiﬁed by phylogenetic tree analysis
of sequencing results.
Results: Serum samples from 55 patients were collected
(41 males and 14 females). Mean age was 39.69 years
(17 64 years). Mean treatment time of adefovir before
viral breakthrough was 19.11 months (5 36 months) and
mean HBVDNA level between adefovir treatment was
5.51 log10 copies/ml (3.01 7.32). 49/55 cases were HBeAg
positive and 6/55 cases were anti-HBe positive. 13 cases
were infected with genotype B2 HBV and 42 cases with
genotype C2. Adefovir resistance was detected in 19/55
cases (34.55%): 5 cases with rtA181T mutation; 3 cases with
rtA181T+rtN236T mutations; 8 cases with rtA181V mutation;
1 case with rtA181V+rtN236T mutations and 3 cases with
rtN236T mutation. There are no differences in treatment
time (22.15 months versus 17.51 months, P > 0.05) and initial
HBVDNA level (5.39 versus 5.56, P > 0.05) between patients
with adefovir resistance mutations and without mutations.
There is no difference in adefovir resistance between
HBeAg positive and negative patients (16/49 versus 3/6,
P > 0.05). Also there is no difference in adefovir resistance
between genotype B2 group and C2 group (3/13 versus
16/42, P > 0.05). Especially, the rtA181T mutation in all
7 cases had sW172stop mutation in the overlapping HBsAg
protein, which results in truncation of HBsAg. And 6/7 cases
had increase in HBVDNA level of 1 2 log10 copies/ml over
6 months. But 1/7 cases had increase of 4.27 log10 copies/ml
over 12 months which is different from previous reports.
Conclusion: There are no differences in adefovir resistance
between HBV genotype B2 and HBV genotype C2 and
between HBeAg positive and anti-HBe Positive patients in
Chinese. And we ﬁnd one rtA181T mutation patient with
HBVDNA level increase of 4.27 log10 copies/ml.
PP-008 Quantiﬁcation of hepatitis B virus total DNA and
covalently closed circular DNA in cirrhosis of
hepatitis B patients’ serum and liver biopsies
Y. Li *, T. Han. Tianjin Medical University Graduate Schools,
Tianjin Third Central Hospital, Tianjin 300170, China
Aim: To quantify hepatitis B virus (HBV) total DNA and
covalently closed circular DNA (cccDNA) in liver biopsies and
sera which from cirrhosis patient caused by HBV infection
and research their application in clinical.
Methods: Total HBVDNA and cccDNA in serum and in liver
biopsy samples were measured in 60 liver cirrhosis patients
by the real-time PCR assay. ALT, TBIL were measured by
ELISA.
Results: 59 out of 60 (98.3%) total HBVDNA was positive in
serum and liver biopsy samples. CccDNA was all negative
in serum samples.24 out of 60 (40%) cccDNA was positive
in liver biopsy samples, positive proportion in 9 HBeAg-
positive, 17 HBeAg-negative anti-HBe- negative, 34 anti-
HBe- positive was 66.7%, 52.9% and 26.5%, respectively.
The levels of total HBVDNA, cccDNA in liver biopsy samples
and total HBVDNA in serum samples decreased progressively
in the above three groups, moreover HBeAg-positive group
had signiﬁcantly higher levels than the anti-HBe- positive
group (log [total serum HBVDNA] P= 0.032; log [total
intrahepatic HBVDNA] P= 0.004; log [intrahepatic cccDNA]
P= 0.017). Total intrahepatic HBVDNA correlated well with
intrahepatic cccDNA (r = 0.534, P< 0.01) and total HBVDNA in
serum samples (r = 0.885, P< 0.01). No correlation between
Total HBVDNA in serum samples and intrahepatic cccDNA
(r = 0.177, P= 0.177). Intrahepatic total HBVDNA, cccDNA
and total HBVDNA in serum samples had no correlation with
ALT, TBIL.
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Conclusions: The replication activity of hepatitis B virus in
HBeAg-positive group was higher than another two groups.
The virus replicated actively and liver function damage
by no means synchronization occurrence. Total HBVDNA
in serum samples combined with intrahepatic cccDNA can
better monitor the anti-viral therapy effect and prognosis.
Abbreviation: Alanine aminotransferase (ALT), total
bilirubin (TBIL), hepatitis B e antigen (HBeAg)
PP-009 Short hairpin RNA with 2 4 bases mismatch
inhibiting B and C genotype HBV in vitro
X.G. Li1 *, J. Cheng2. 1Infectious Disease Department of
the Second Afﬁliated Hospital in Harbin Medical University,
Harbin, China, 2Infectious Disease Institute of Beijing
Ditan Hospital, Beijing, China
Until recently, only alpha interferon and nucleotides
(analogue) were available for the treatment of HBV.
However, the low efﬁcacy, undesirable side-effects, and
drug- resistance remain the major obstacles in treating HBV
infection, the need for alternative therapeutic measures has
provided the impetus to develop novel therapeutic reagents
for inhibiting HBV replication.
RNAi has proven to be very powerful in inhibiting HBV
replication by cell culture and mouse model studies. The
present study all designed perfect match siRNAs to target
HBV, as we all known that HBV exist as quasispecies, so, it
is essential to study inhibitory effect of mismatched siRNAs
on target HBV; here, we study the inhibitory effect of 2 4
bases mismatch shRNAs on HBV.
Objective: To assess the inhibitory effect of shRNAs with
mismatching with target sequence on B and C genotype
HBV.
Methods: shRNA and pHY106-BHBV or pHY106-CHBV
cotransfected HepG2 cells, the supernatant of the culture
at 24 h, 48 h, 72 h, 96 h and 120 h after cotransfection
was collected and frozen in 20ºC for examining HBsAg
and HBeAg by ELISA; 72 h after cotransfection, the total
RNA of cells was exstracted and reverse-transcripted, then
detecting the level of HBsAg mRNA by RT-PCR; 72 h
after cotransfection, cells were lysated, HBV replicative
intermediate from HBV core particles was exstracted for
southern blot.
Results 1. HBsAg and HBeAg expression were inhibited
obviously by shRNA458 and shRNA635, the inhibitory effect
was detectable at 48 h after cotransfection, the peak time
was 72 h, the most inhibitory ratio was approximately 80%
and 50% in HBsAg and HBeAg; there was no difference
was observed about the the inhibitory action of shRNA458
and shRNA635 on B or C genotype HBV; 2. shRNA458
and shRNA635 had the similar inhibitory action on the
production of HBsAg mRNA in B and C genotype HBV at
72 h after cotransfection, the inhibitory ratio was 60 70%;
3. HBV replicative intermediate from B and C genotype HBV
was inhibited obviously by the two shRNAs also.
Conclusions shRNA458 and shRNA635 have powerfully
inhibitory effect on the expression of HBsAg and HBeAg,
HBsAg mRNA and HBV replication although 2 4 bases
mismatch between shRNAs and target HBV, so shRNA458
and shRNA635 are two powerful tools for inhibiting HBV.
PP-010 3D structural and dynamic features of Protein-x
of hepatitis B virus
A. Mohamadkhani1 *, Z. Minuchehr1, A. Madadkar
Sobhani2, M. Sotoudeh3, H. Poustchi3, F. Rastgar Jazii1,
R. Malekzadeh3. 1National Institute of Genetic Engineering
and Biotechnology Tehran, Iran, 2Institute of Biochemistry
and Biophysics, University of Tehran, Tehran, Iran,
3Digestive Disease Research Centre, Shariati Hospital,
Medical Science/University of Tehran, Tehran, Iran
Background and Aim: The protein-x of Hepatitis B virus
(HBx) interacted directly or indirectly with host factors
to modulate cell signaling pathways and would have
suggested being oncogenic. Though many functions have
been associated with protein-x, the nature of this protein
is not well disclosed. Full understanding of the biological
role of this protein will require a complete knowledge of
its structure. Here we present a structural model to picture
the structure of HBx using computational approaches along
with the available experimental data.
Methods: Protein-x was translated based on its genome
which we have sequenced previously. Bioinformatics tools
were employed for searching Hidden Markov Model and
conserved motif(s). SSpro program was performed to
determine the secondary structure of the protein and the
ProtScale program was used to provide several predeﬁned
amino acid scales. Our model was constructed using 1jfua as
a template by LOMETS server. Optimization of the model was
carried out by the molecular dynamics simulated method.
Results: Analysis of the amino acid sequences of HBx by
pfam database clariﬁed a large conserved domain and motif
search showed a Trans-activation region for protein-x. PSI-
Blast revealed not more than 26% identity against the PDB
database.
Reﬁned model included a stable folding with a coiled
motif and three helical domains with two antiparallel
b-sheets. The model was tested using molecular dynamics
simulation.
Conclusion: Although there is limited knowledge about
protein-x of hepatitis B virus, here we modeled a unique
3D structure for the ﬁrst time. The model was tested for
validation and dynamic simulations in water. This model can
lead to better understanding of the function of protein-x
and its interaction with the cellular proteins that could be
useful for the design of selective inhibitors as a target in
treatment.
PP-011 An undamaged bulge of e is essential
for initiating priming of DHBV reverse
transcriptase
K.H. Hu1,2 *, F. Hui1, L. Hui1. 1State Key Laboratory of
Virology, Wuhan Institute of Virology, Chinese Academy of
Sciences, Wuhan 430071, China, 2Institute of Molecular and
Cellular Anatomy, University of Regensburg, Regensburg,
D-93053, Germany
Hepatitis B virus (HBV), the type member of the
Hepadnaviridae, is responsible for infections that cause
B-type hepatitis. The small enveloped HBV virus replicates
via reverse transcription of an intermediate RNA-the
pregenomic RNA (pgRNA), and initiates by protein-priming
to the epsilon (e) stem-loop on the pgRNA. The e hairpin
consists of a lower stem, an apical loop, an upper stem,
and a bulge region which serves as template of priming,
i.e. 3 or 4 nt de novo DNA synthesis. e is essential for
the encapsidation of the pgRNA and initiation of reverse
transcription. Both events are mediated by binding of
reverse transcriptase (P protein) plus cellular chaperones
to e RNA. However, within e, little information is known
which structural elements are indispensable for priming.
